ASCO 2025 — Let’s Talk About What’s Next in Oncology

Read article

Bill Taaffe Joins Medelis as President

Medelis is pleased to announce that Bill Taaffe,…
Read Article

How Immune-related Response Criteria Is Changing Immunotherapy Treatments

Immune-related response criteria (irRC) is an essential tool…
Read Article

Deciding Between a Large CRO and a Boutique CRO for Your Oncology Study

When it’s time to evaluate CROs for your…
Read Article

Regulatory Strategy for In Vitro Companion Diagnostic Devices

Final FDA Guidance for In Vitro Companion Diagnostics…
Read Article

FDA Guidance Finalizes Position on In Vitro Companion Diagnostic Devices

As more targeted therapies are developed - defined…
Read Article

Medelis Partners With Insight Genetics to Deliver Molecular Diagnostics to Oncology Sponsors and Patients

Increasing the effectiveness of cancer treatments is an…
Read Article

Things to Remember When Planning Your Phase I Oncology Study

Oncology trials are complex, especially first-in-human phase I…
Read Article

The Importance of Bid Transparency in a CRO Proposal

Planning an oncology study requires a tremendous amount…
Read Article

The PD-1 Era Is Officially Here

On July 4th Ono Pharmaceuticals announced that it…
Read Article